Filing Details
- Accession Number:
- 0001104659-25-020984
- Form Type:
- 13D Filing
- Publication Date:
- 2025-03-04 19:00:00
- Filed By:
- Charles Cherington
- Company:
- Eterna Therapeutics Inc. (NYSEMKT:ERNA)
- Filing Date:
- 2025-03-05
- SEC Url:
- 13D Filing
Ownership Summary
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Charles Cherington | 16,642,183 | 0 | 16,642,183 | 0 | 16,642,183 | 32.38% |
Filing
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 5)
|
Eterna Therapeutics Inc. (Name of Issuer) |
Common Stock, par value $0.005 per share (Title of Class of Securities) |
114082209 (CUSIP Number) |
Charles Cherington c/o Ara Partners, LLC,, 200 Berkeley Street, 26th Floor Boston, MA, 02116 (617) 838-3053 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
10/29/2024 (Date of Event Which Requires Filing of This Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
| CUSIP No. | 114082209 |
| 1 |
Name of reporting person
Charles Cherington | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
PF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
UNITED STATES
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
16,642,183.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
32.38 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IN |
Comment for Type of Reporting Person:
Rows 7, 9 and 11 consist of (i) 16,628,123 shares of common stock, par value $0.005 per share (the "Common Stock"), of Eterna Therapeutics Inc. (the "Issuer") and (ii) 14,060 shares of Common Stock issuable upon conversion of 71,306 shares of Series A convertible preferred stock of the Issuer (assuming a conversion rate of 5.0717).
Row 13 is calculated based on an aggregate of 51,388,773 shares of Common Stock of the Issuer outstanding, which is calculated by adding (i) 51,374,713 shares of common stock of the Issuer outstanding as of as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission ("SEC") on November 12, 2024 and (ii) 14,060 shares of Common Stock issuable upon conversion of 71,306 shares of Series A convertible preferred stock within 60 days, which are deemed outstanding pursuant to Rule 13-3(d)(1)(i).
SCHEDULE 13D
|
| Item 1. | Security and Issuer | |
| (a) | Title of Class of Securities:
Common Stock, par value $0.005 per share | |
| (b) | Name of Issuer:
Eterna Therapeutics Inc. | |
| (c) | Address of Issuer's Principal Executive Offices:
1035 Cambridge Street, Suite 18A, Cambridge,
MASSACHUSETTS
, 02141. | |
Item 1 Comment:
Pursuant to Rule 13d-2 promulgated under the Securities Exchange Act of 1934, as amended, this Amendment No. 5 to Schedule 13D (this "Amendment No. 5") amends certain Items of the Schedule 13D originally filed with the SEC on May 13, 2021 (the "Original Schedule 13D"), as amended by Amendment No. 1 thereto filed with the SEC on March 16, 2022 ("Amendment No. 1"), Amendment No. 2 thereto filed with the SEC on December 14, 2022 ("Amendment No. 2"), Amendment No. 3 thereto filed with the SEC on September 7, 2023 ("Amendment No. 3") and Amendment No. 4 thereto filed with the SEC on December 20, 2023 ("Amendment No. 4," and the Original Schedule 13D, as amended by Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No. 4 and this Amendment No. 5 are collectively referred to herein as the "Schedule 13D") by furnishing the information set forth below. Except as set forth below, all previous Items are unchanged. | ||
| Item 3. | Source and Amount of Funds or Other Consideration | |
The information provided in Item 5 of this Amendment No. 5 is incorporated by reference to this Item 3. | ||
| Item 4. | Purpose of Transaction | |
Item 4 is hereby amended by adding the following: The Reporting Person acquired 16,071,658 shares of Common Stock of the Issuer pursuant to the Exchange Transactions (as defined below) and the Notes Conversion (as described below). The Reporting Person has no present plan or proposal that relates to, or could result in, any of the events referred to in paragraphs (a) through (j) inclusive, of Item 4 of Schedule 13D. | ||
| Item 5. | Interest in Securities of the Issuer | |
| (a) | As of February 18, 2025, the Reporting Person owned directly (i) 16,628,123 shares of Common Stock of the Issuer and (ii) 14,060 shares of Common Stock issuable upon conversion of 71,306 shares of Series A convertible preferred stock of the Issuer (assuming a conversion rate of 5.0717). Rows 11 and 13 set forth on the cover page to this Amendment No. 5 are hereby incorporated by reference in this Item 5 (a). | |
| (b) | Rows 7 through 10, inclusive, set forth on the cover page to this Amendment No. 5 are hereby incorporated by reference in this Item 5(b). | |
| (c) | On September 23, 2024, the Reporting Person acquired the rights to $240,000 in aggregate principal amount of the Issuer's 6.0% Senior Convertible Promissory Notes due 2028 (the "2028 Notes") and 167,832 warrants (the "Assigned Warrants") to purchase one share of Common Stock per Assigned Warrant in exchange for agreeing to forgive an aggregate of $100,000 in personal loans to two investors.
On October 29, 2024, the Reporting Person acquired $1,368,626 in aggregate principal amount of the Issuer's 12% Senior Convertible Notes due September 24, 2025 (the "2025 Notes") and 5,474,504 accompanying warrants (the "2024 Warrants") to purchase one share of Common Stock per 2024 Warrant. The Reporting Person acquired the 2025 Notes and 2024 Warrants from the Issuer in a private placement pursuant to that certain Securities Purchase Agreement, dated as of September 24, 2024, by and among the Issuer, the Reporting Person and the other parties thereto.
Following the issuance of the 2025 Notes and the 2024 Warrants on October 29, 2024, the Reporting Person consummated an exchange with the Issuer (the "Warrant Exchange") of (i) warrants to purchase an aggregate of 261,756 shares of Common Stock issued in December 2022 with an exercise price of $1.43 per share (the "2022 Warrants"); (ii) warrants to purchase an aggregate of 1,153,846 shares of Common Stock issued in July 2023 with an exercise price of $1.43 per share (the "July 2023 Warrants"); (iii) warrants to purchase an aggregate of 1,562,988 shares of Common Stock issued in December 2023 with an exercise price of $1.43 per share (the "December 2023 Warrants" and together with the 2022 Warrants, the July 2023 Warrants, the Assigned Warrants and the 2024 Warrants, the "Warrants");(iv) the Assigned Warrants; and (v) the 2024 Warrants. Each Warrant was exchanged for shares of Common Stock at an exchange ratio of 0.5 of a share of Common Stock per Warrant or Note, resulting in the acquisition of 4,310,463 shares of Common Stock by the Reporting Person.
At the same time as the Warrant Exchange, the Reporting Person consummated an exchange with the Issuer (the "Notes Exchange" and together with the Warrant Exchange, the "Exchange Transactions") of (i) $3.54 million in the aggregate principal amount of the Issuer's 6.0% Senior Convertible Promissory Notes due 2028 (the "6.0%Notes") and (ii) $3.0 million in the aggregate principal amount of the Issuer's 12.0% Senior Convertible Notes due December 12, 2028 (the "12.0% Notes"). All of the 6.0% Notes and the 12.0% Notes were exchanged for shares of Common Stock at an exchange ratio equal to (A) the sum expressed in U.S. dollars of (1) the principal amount of the applicable convertible note, plus (2) all accrued and unpaid interest thereon through the date the applicable convertible note is exchanged plus (3) all interest that would have accrued through, but not including, the maturity date of applicable convertible note if it was outstanding from the date such convertible note is exchanged through its maturity date, divided by (B) $1.00 (rounded up to the nearest whole number), resulting in the acquisition of 8,941,649 shares of Common Stock by the Reporting Person.
Concurrently with the Exchange Transactions, the 2025 Notes plus all accrued and unpaid interest thereon were automatically converted (the "Notes Conversion") at a conversion price of $0.50 per share of Common Stock into 2,819,546 shares of Common Stock.
The Exchange Transactions and Notes Conversion were approved by the Issuer's stockholders at the Issuer's Annual Meeting of Stockholders on October 29, 2024. | |
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|